Clinical Trial Update: Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating sintilimab for undifferentiated pleomorphic sarcoma; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Undifferentiated Pleomorphic Sarcoma

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma | Phase 2 | Status: TERMINATED | Results posted: 2024-11-12